AI-generated analysis. Always verify with the original filing.
Vaxart, Inc. announced full year 2025 financial results with revenue of $237.3 million, net income of $16.3 million, and cash of $63.8 million providing runway into Q2 2027. Key highlights include topline data from COVID-19 Phase 2b sentinel cohort expected early Q2 2026 and worldwide collaboration with Dynavax.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 12, 2026, Vaxart, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its finan
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 12, 2026. 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Revenue | $237.3K | GAAP |
| Research and Development Expenses | $201.6K | GAAP |
| General and Administrative Expenses | $17.6K | GAAP |
| Operating Income | $18.1K | GAAP |
| Net Income | $16.3K | GAAP |
| Net Income per Share | $0.07 | GAAP |